Gedeon Richter presents new data on cariprazine's cognitive effects in schizophrenia
Gedeon Richter Plc. has presented new scientific research data on the benefits of cariprazine in treating cognitive symptoms in patients with schizophrenia. The data were presented at the WFSBP 2021 congress.
Budapest, Hungary – Gedeon Richter Plc. has presented new research data regarding the effects of cariprazine, its schizophrenia medication, on cognitive symptoms.
The new data were unveiled at the World Federation of Societies of Biological Psychiatry (WFSBP) 2021 congress. The study focused on cariprazine's ability to improve cognitive functions in patients suffering from schizophrenia.
Cariprazine is already recognized for its efficacy in managing positive and negative symptoms of schizophrenia. This recent data suggests the medication may offer significant advantages concerning patients' cognitive abilities, such as memory and attention.
Gedeon Richter continues to actively investigate the benefits and applications of cariprazine to enhance the quality of life for individuals with mental health conditions.